[ACOR] Acorda Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 1.15 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 18.15 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart ACOR

Refresh chart

Strongest Trends Summary For ACOR

ACOR is in the long-term down -62% below S&P in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. The company?s products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain. It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the trea

Fundamental Ratios
Shares Outstanding46.07 M EPS-1.16 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.8% Sales Growth - Q/Q-15.29% P/E-14.87
P/E To EPS Growth P/S2.74 P/BV2.1 Price/Cash Per Share3.83
Price/Free Cash Flow16.48 ROA1.26% ROE2.53% ROI1.53%
Current Ratio3.47 Quick Ratio3.09 Long Term Debt/Equity0.96 Debt Ratio0.22
Gross Margin80.15% Operating Margin7.54% Net Profit Margin3.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.63 M Cash From Investing Activities-116.04 M Cash From Operating Activities-9.25 M Gross Profit90.84 M
Net Profit1000 K Operating Profit5.69 M Total Assets1.1 B Total Current Assets408.31 M
Total Current Liabilities460.01 M Total Debt292.68 M Total Liabilities540.27 M Total Revenue113.71 M
Technical Data
High 52 week32.6 Low 52 week13.8 Last close32.6 Last change7.24%
RSI96.12 Average true range1.73 Beta1.06 Volume622.39 K
Simple moving average 20 days27.01% Simple moving average 50 days34.29% Simple moving average 200 days35.16%
Performance Data
Performance Week23.72% Performance Month38.14% Performance Quart27.34% Performance Half57.11%
Performance Year92.9% Performance Year-to-date51.98% Volatility daily2.78% Volatility weekly6.22%
Volatility monthly12.76% Volatility yearly44.18% Relative Volume329.71% Average Volume497.09 K
New High New Low

News

2020-06-04 11:31:03 | Acorda ACOR Down 11.8% Since Last Earnings Report: Can It Rebound?

2020-06-03 09:05:01 | Acadia Healthcare Ties Up for Improved Behavioral Services

2020-05-06 19:23:00 | DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600

2020-05-06 13:27:05 | Acorda ACOR Q1 Earnings Lag Estimates, Revenues Fall Y/Y

2020-05-05 18:15:10 | Acorda Therapeutics ACOR Reports Q1 Loss, Misses Revenue Estimates

2020-05-05 16:00:00 | Acorda Reports First Quarter 2020 Financial Results and Provides Business Update

2020-04-28 07:00:00 | Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020

2020-04-24 11:49:03 | Acorda ACOR to Report Q1 Earnings: What's in the Cards?

2020-04-16 17:45:09 | Acorda Therapeutics ACOR Flat As Market Gains: What You Should Know

2020-04-07 17:50:09 | Acorda Therapeutics ACOR Stock Moves -0.11%: What You Should Know

2020-04-07 12:37:04 | Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study

2020-04-07 11:14:03 | Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue

2020-04-03 08:31:12 | Immunomedics IMMU in Focus: Stock Moves 5% Higher

2020-04-02 10:08:02 | Nabriva NBRV Looks Good: Stock Adds 5.7% in Session

2020-03-30 08:06:12 | New Strong Buy Stocks for March 30th

2020-03-17 12:00:04 | What Makes Acorda ACOR a New Buy Stock

2020-03-14 11:30:03 | Why Is Acorda ACOR Down 54.7% Since Last Earnings Report?

2020-02-24 07:00:00 | Acorda Therapeutics to Present at Cowen Annual Health Care Conference

2020-02-17 21:01:43 | Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMT

2020-02-14 11:57:04 | Acorda ACOR Q4 Earnings Top Estimates, Revenues Fall Y/Y

2020-02-13 10:25:03 | Acorda Therapeutics ACOR Reports Q4 Loss, Tops Revenue Estimates

2020-02-13 09:15:02 | Acorda ACOR Beats Earnings & Revenues Estimates in Q4

2020-02-13 07:00:00 | Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-10 10:20:03 | What's in Store for Acorda ACOR This Earnings Season?

2020-02-06 12:31:05 | Earnings Preview: Acorda Therapeutics ACOR Q4 Earnings Expected to Decline

2020-02-06 05:51:23 | Acorda Therapeutics, Inc. NASDAQ:ACOR: What Does Its Beta Value Mean For Your Portfolio?

2020-01-30 07:00:00 | Acorda Fourth Quarter/Year End 2019 Update: Webcast/Conference Call Scheduled for February 13, 2020

2020-01-24 08:54:01 | Implied Volatility Surging for Acorda ACOR Stock Options

2020-01-15 07:00:00 | Acorda Provides 2019 Highlights and 2020 Guidance at J.P. Morgan Healthcare Conference

2020-01-08 07:00:00 | Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference

2020-01-07 10:55:03 | Acorda Therapeutics ACOR in Focus: Stock Moves 5.7% Higher

2020-01-03 07:55:22 | The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

2019-12-26 07:00:00 | Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024

2019-12-23 05:30:00 | Acorda Therapeutics Announces Private Exchange of $276 Million of Its 1.75% Convertible Senior Notes Due 2021

2019-12-12 10:31:56 | Hedge Funds Are Getting Burned By Acorda Therapeutics Inc ACOR

2019-12-04 11:30:04 | Acorda ACOR Down 13.5% Since Last Earnings Report: Can It Rebound?

2019-12-02 10:22:03 | Acorda ACOR Down More Than 80% Year to Date: Here's Why

2019-11-27 07:00:00 | Acorda Therapeutics Elects John Kelley Chair, Board of Directors

2019-11-12 07:00:00 | Acorda Therapeutics Announces Departure of President, International & General Counsel

2019-11-08 10:21:43 | Is Acorda Therapeutics, Inc.'s NASDAQ:ACOR CEO Paid Enough Relative To Peers?

2019-11-07 11:08:04 | Zoetis ZTS Beats on Earnings in Q3, Reports In-Line Sales

2019-11-07 11:05:04 | Horizon Therapeutics' HZNP Q3 Earnings Beat Estimates

2019-11-07 11:04:04 | Esperion ESPR Reports Wider-Than-Expected Loss in Q3

2019-11-07 08:50:01 | Geron GERN Q3 Earnings Beat Estimates, Stock Gains 4.1%

2019-11-06 16:40:57 | Were Hedge Funds Right About Dumping Acorda Therapeutics Inc ACOR?

2019-11-06 16:28:46 | Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMT

2019-11-06 10:56:03 | Perrigo PRGO Beats on Q3 Earnings, Tightens '19 EPS View

2019-11-06 10:34:03 | Intercept ICPT Earnings and Sales Miss Estimates in Q3

2019-11-05 11:45:04 | Acorda ACOR Q3 Earnings and Revenues Surpass Estimates

2019-11-05 11:09:04 | Agenus AGEN Q3 Earnings Beat Estimates, Revenues Up Y/Y